The ongoing legal battle between Apple and Masimo over the blood oxygen sensor in Apple Watch devices has taken an intriguing turn. The US International Trade Commission (ITC) has recently declined Masimo's request for another import ban on the Apple Watch, marking a significant victory for Apple. This decision opens up the possibility of Apple reintroducing the blood oxygen monitoring feature in its devices, which was previously disabled due to the patent dispute. However, the story doesn't end here, as Masimo may still have legal avenues to explore.
The ITC's ruling is a pivotal moment in this legal saga. In 2023, the ITC had initially sided with Masimo, imposing an import ban on the Apple Watch Series 9 and Ultra 2 models. Apple responded by temporarily disabling the blood oxygen sensing feature in these devices. However, the ITC's recent decision to not review the preliminary ruling suggests that Apple's redesigned watches do not infringe on Masimo's patents. This means Apple can now potentially bring back the blood oxygen monitoring feature, which has been a point of contention for years.
The history of this case is complex and filled with twists and turns. In 2020, Apple launched the Series 6 Apple Watch with the blood oxygen sensor, which measures blood oxygen saturation (SpO2). Masimo, a global medical technology company, filed a lawsuit claiming patent infringement. The ITC became involved in 2021 and, in 2023, upheld that Apple violated Masimo's patents, leading to the import ban. Apple's response was to disable the blood oxygen feature, causing some inconvenience for users who relied on this health monitoring capability.
The story took an interesting turn when Apple reintroduced the blood oxygen sensing feature in the Apple Watch Series 11, using a paired iPhone to display the blood oxygen levels. This move sparked a lawsuit by Masimo against US Customs, but the ITC's recent decision suggests that Apple's approach was legal. However, Masimo's November win in a California jury verdict, awarding them $634 million in damages for patent infringement, adds another layer of complexity. Masimo's commitment to defending its intellectual property rights indicates that the legal battle may not be over yet.
For now, Apple can breathe a sigh of relief, but the possibility of further legal action looms. The ITC's decision provides Apple with an opportunity to restore a valuable health feature, but it also highlights the ongoing challenges in the tech industry regarding intellectual property rights. As the story unfolds, it serves as a reminder of the intricate legal battles that can arise from seemingly minor innovations, and the potential impact on consumers and companies alike.
